Cryo-Cell International (STU:ZCY) EBIT: €-0.66 Mil (TTM As of Feb. 2026)


STU:ZCY Cryo-Cell International Inc STU:ZCY
58 GF Score
Price €3.10
GF Value €6.10
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cryo-Cell International EBIT?

Cryo-Cell International STU:ZCY -2.52% 58 EBIT is €-0.66 Mil as of Feb. 2026. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €6.10 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cryo-Cell International's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2026 was €0.45 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was €-0.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cryo-Cell International's annualized ROC % for the quarter that ended in Feb. 2026 was 3.31%. Cryo-Cell International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was 9.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cryo-Cell International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -2.40%.


Cryo-Cell International  (STU:ZCY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cryo-Cell International's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=2.588 * ( 1 - 32.2% )/( (54.162 + 51.93)/ 2 )
=1.754664/53.046
=3.31 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Cryo-Cell International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.804/( ( (18.904 + max(-7.28, 0)) + (18.265 + max(-6.234, 0)) )/ 2 )
=1.804/( ( 18.904 + 18.265 )/ 2 )
=1.804/18.5845
=9.71 %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.922 + 0.354 + 1.044) - (6.184 + 8.416 + -3.5527136788005E-15)
=-7.28

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.766 + 0.302 + 0.85) - (5.236 + 7.916 + 0)
=-6.234

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cryo-Cell International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-0.659/27.439
=-2.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryo-Cell International EBIT Related Terms


Cryo-Cell International EBIT Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International EBIT Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.50 4.75 -11.21 4.40 -0.23

Cryo-Cell International Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 1.00 1.48 -3.59 0.45

STU:ZCY vs CCM, CDIX, EHSI: EBIT Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's EV-to-EBIT falls into.


STU:ZCY
58GF Score
Cryo-Cell International Inc STU:ZCY
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-0.66 Mil mean?
Cryo-Cell International (STU:ZCY) has a EBIT of €-0.66 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cryo-Cell International.
Is Cryo-Cell International's EBIT too high?
Cryo-Cell International's current EBIT is €-0.66 Mil. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's EBIT compare to CCM and CDIX?
Cryo-Cell International's EBIT of €-0.66 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cryo-Cell International. Cryo-Cell International's current EBIT is €-0.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €6.10, compared to a current price of €3.10 — trading 49.2% below its estimated fair value. The current EBIT is €-0.66 Mil. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current EBIT is €-0.66 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €3.10 is trading 49.2% below its estimated GF Value™ of €6.10. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for STU:ZCY:

  • EBIT: €-0.66 Mil
  • GF Value™: €6.10 vs. price of €3.10 (49.2% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryo-Cell International Business Description

Other Exchanges CCEL:USAZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score

Get the complete analysis for STU:ZCY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.10
Price
€6.10
GF Value